Kornimate/medical-research-clean huggingface dataset:
a virtual reality system for pain and anxiety management during outpatient hysteroscopy

Conditions: Infertility; Vaginal Blood Loss

Summary: to evaluate the effectiveness of vr as a distraction technique in the management of acute pain and anxiety during operative hysteroscopy in the outpatient setting.

a prospective, open-label, randomized control trial in a tertiary university-affiliated medical center between april to august 2020. overall, 100 women will be randomly allocated to undergo operative hysteroscopy either with the use of vr (study group) or with standard treatment (control group). the primary outcome measures includ self-reported pain, anxiety scores, and vital parameters as pulse rate (pr) and respiratory rate (rr). pain and anxiety outcomes were measured as numeric rating scores.

Eligibility criteria:
inclusion criteria: * . women with suspected infection * women considered not suitable to undergo an office hysteroscopy * women who reported the use of analgesia 6 hours prior to the procedure. exclusion criteria: * patient needed office hysteroscopy

Keywords: hysteroscopy vr vurtual reality
role of rosiglitazone on pre-diabetes mellitus and coronary artery disease

Conditions: Prediabetes; Coronary Artery Disease; Insulin Resistance; Glucose Intolerance

Summary: objectives: the investigators examined whether rosiglitazone, a thiazolidinedione (tzd), is beneficial for pre-diabetes mellitus (dm) adults with documented coronary artery disease (cad). background: microvascular and macrovascular complications are common in type 2 dm. there is no evidence about the effects of tzds, synthetic peroxisome proliferator-activated receptor (ppar)-γ activators (insulin sensitizers and adipose transcriptional regulation and anti-inflammatory process activators) on pre-dm patients with documented cad.

materials and methods: this is a randomized, double-blind, placebo-controlled study, patients will be randomly assigned to the tzd group and to the placebo group with a 6-month treatment period. biomarkers will also examined before and 6 months post-treatment during the trial. the primary end-points will be the diagnosis of major cardiovascular events: myocardial infarction, overt heart failure, and surgery or coronary intervention for cad.

Eligibility criteria:
inclusion criteria: * documented cad by angiography * insulin resistance or glucose intolerance * 18 to 80 years of age exclusion criteria: * under dm treatment * allergy to tzd * active inflammation * chronic disease under nsaid treatment * active heart failure * unwilling or unable to sign inform consents

Keywords: prediabetes coronary artery disease insulin resistance glucose intolerance
deciphering a specific signature of the immunosenescence induced in covid-19+ patients versus rheumatoid arthritis patients

Conditions: SARS-Cov-2 Infection; Rheumatoid Arthritis

Summary: immune aging or immunosenescence is characterized by a loss of t cell clonal diversity and a contraction of naïve t cells with proliferative capacity associated with the functional impairment of many others immune cells as well as a chronic low degree of inflammation. a restrictive t cell repertoire is likely more prone to antigen-mediated exhaustion observed during chronic viral infections. notably, lymphopenia is the most consistent laboratory abnormality in covid-19 infected patients and both lung-resident and circulating t cells potently up-regulate markers of t cell exhaustion. it is not clear today if the association of covid-19 disease severity with age is mainly related with the immunosenescence of infected patients. interestingly, t cell exhaustion and premature immunosenescence have also been observed in chronic inflammatory diseases such as rheumatoid arthritis (ra). to better understand the immunological mechanisms involved in sars-cov-2 pathophysiology, the investigators propose to compare the immunosenescence patterns observed during ra, aging and sars-cov-2 infected patients in order to design improved therapeutic interventions.


Eligibility criteria:
inclusion criteria for active ra patients: * patients with rheumatoid arthritis (ra) meeting the 2010 acr/eular diagnostic criteria * patients in inflammatory flare of ra (das28 \> 3.2) * patients who have been off biological disease-modifying antirheumatic drugs (bdmards) or targeted synthetic antirheumatic drugs (tsdmards) for ra for at least 2 weeks (except for rituximab, where a delay of at least 12 months is required) * conventional synthetic dmards (methotrexate, hydroxychloroquine, leflunomide, sulfasalazine) are allowed * beneficiary of a social security system * informed consent inclusion criteria for healthy controls: * absence of chronic diseases and current infection * beneficiary of a social security system * informed consent inclusion criteria for covid-19+ patients: * patients with ongoing sars-cov-2 infection (pcr+) * patients hospitalized at d7-d14 of symptoms onset * patients with two or more sars-cov-2 symptoms (including fever, cough, dyspnea, sore throat, chest pain, anosmia, diarrhea) * membership in or beneficiary of a social security scheme * collection of free and informed consent exclusion criteria for all groups: * subjects under 18 years of age * hiv positive patients * diabetic patients * morbidly obese patients (bmi \> 40kg/m2) * use of senolytic drugs in the week prior to inclusion (azithromycin, metformin, cyclosporine, jak inhibitors) * use of steroids in doses greater than 10 mg/day in the week prior to inclusion * subjects unable to give consent * pregnant, breastfeeding, or non-menopausal women not taking effective contraception * vulnerable subjects protected by law * subjects under guardianship or curatorship
the influence of passive leg elevation on the cross-sectional area of the internal jugular vein in infants or young children undergoing open heart surgery

Conditions: Infants or Children Undergoing Open Heart Surgery

Summary: the trendelenburg position is usually applied to increase the cross-sectional area of the ijv. however, trendelenburg position requires a tilt table to place the head in the down position. trendelenburg position could also increase intracranial pressure. passive leg elevation redistributes more blood from the lower extremity into the central veins and is proved to increase the cross-sectional area of ijv in adults. however, the effect of leg elevation on the cross-sectional area of ijv in small infants and children has not been evaluated. the investigators evaluated the effect of passive leg elevation on the cross-sectional area of ijv in subjects undergoing open heart surgery for congenital anomaly.

internal jugular vein (ijv) cannulation is essential for open heart surgery of small infants and children for transfusion or inotropics infusion. the trendelenburg position is usually applied to increase the cross-sectional area of the ijv. however, trendelenburg position requires a tilt table to place the head in the down position. trendelenburg position could also increase intracranial pressure. passive leg elevation redistributes more blood from the lower extremity into the central veins and is proved to increase the cross-sectional area of ijv in adults. however, the effect of leg elevation on the cross-sectional area of ijv in small infants and children has not been evaluated. furthermore, the children undergoing open heart surgery due to cardiac anomaly have an altered hemodynamics and often congested right heart. therefore, the response of passive leg elevation may be different from that of normal heart physiology. therefore, we evaluated the effect of passive leg elevation on the cross-sectional area of ijv in subjects undergoing open heart surgery for congenital anomaly.

Eligibility criteria:
inclusion criteria: * infants or children under 5 yrs undergoing elective open heart surgery for congenital anomaly for study period exclusion criteria: * previous history of internal jugular vein cannulation * concurrent pulmonary disease that can influence the hemodynamics of right heart * increased intracranial pressure * hemodynamic unstability

Keywords: internal jugular vein cannulation cross-sectional area passive leg elevation trendelenburg position open heart surgery
development and pilot evaluation of modified cognitive behavioural therapy for adolescents with early onset psychosis

Conditions: Psychotic Disorders; Schizophrenia; Schizoaffective Disorder; Delusional Disorder; Schizophreniform Disorder

Summary: in the last decade cognitive behavioural therapy (cbt) approaches for patients with schizophrenia have been developed, which where especially designed to reduce severity of positive symptoms, readmission rates, treatment non-compliance and disability. although cbt addresses the key problems of early onset psychoses (eop)treatment and first evaluations of cbt in adults with schizophrenia are promising, no experience with cbt in adolescents with eop are available. therefore the present study is conducted to develop a modified cbt (mcbt) for adolescents with eop, to explore its acceptance and feasibility and to provide data for a realistic estimation of achievable effect size. patients are randomized to receive either mcbt+tau or tau over a 9 month period. mcbt is an individual outpatient treatment of 20 session and 5 psychoeducational sessions with parents. follow-ups for two years every 6 months are planned.


Eligibility criteria:
inclusion criteria: * schizophrenia, schizophreniform or schizoaffective disorder (dsm iv 295.1- .9), delusional disorder (dsm iv 297.1) * score of 4 or more on one of the panss-items p1, p3, g9 * positive psychotic symptoms for 3 months or more * age between 14 and 18 * fluently german speaking exclusion criteria: * diagnosis of delirium, dementia, amnestic or other cognitive disorder, psychiatric disorders due to a somatic factor or related to psychotropic substances according to dsm iv; diseases of the central nervous system * alcohol- or drug dependence according to dsm iv * verbal iq \< 80 * travel time to the study centre of more than 1 hour

Keywords: schizophrenia cognitive behavioural therapy early onset psychosis psychotic disorders (schizophrenia, schizoaffective disorder, delusional disorder, schizophreniform disorder according to dsm iv) in adolescents
paraorbital-occipital alternating current stimulation therapy of patients with post-chiasmatic lesions

Conditions: Complete Hemianopia; Incomplete Hemianopia; Scotoma; Quadrantanopia; Stroke; Hemorrhage; Brain Trauma

Summary: visual field areas, which are not absolutely blind, are hypothesized to have some residual capacities that constitute their potential for vision restoration. vision restoration can be achieved by varies methods including behavioral training and electrical brain stimulation such as transcranial direct current stimulation (tdcs) and repetitive transorbital alternating current stimulation (rtacs) which are able to influence the excitability and activity of cortical areas. it is hypothesized that transorbital alternating current stimulation (tacs) can improve the residual field of vision in patients with post-chiasmatic lesions.


Eligibility criteria:
inclusion criteria: * lesion of the tractus opticus or of the visual cortex * lesion age \> 6 months * stable visual field defect with residual vision exclusion criteria: * electric or electronic implants, e.g. heart pacer * any metal artefacts in the head * epilepsy * auto-immune diseases in acute stage * mental diseases, e.g. schizophrenia etc. * diabetic retinopathy * addictive diseases * blood pressure above 160/100 mmhg * instable or high level of intraocular pressure above 27 mmhg * retinitis pigmentosa * pathological nystagmus * presence of an un-operated tumor or tumor relapse (patients with non-progressive tumor are eligible if study participation is recommended by medical authorities) * focal findings in eeg or photosensitivity (patients with single seizure more than 10 yrs ago may participate) * recurrent transitional ischemic attacks after stroke * arteriosclerosis of large blood vessels with stenosis \>75% * severe coronary heart disease (chd) * unstable angina pectoris * diabetes with blood glucose level \> 9 mmol/l * myocard infarct/ cardiomyopathy * ventricular fibrillation * risk of vascular thrombosis * pregnant or breast-feeding women

Keywords: hemianopia visual field defect stroke non-invasive brain stimulation alternating current stimulation
efficacy of alpha tocopherol for prevention of contrast-induced nephropathy in chronic kidney disease (ckd) patients

Conditions: Contrast Induced Nephropathy

Summary: the purpose of this study is to demonstrate the efficacy of alpha tocopherol for prevention contrast-induced nephropathy in ckd patients undergoing elective coronary procedures.

contrast-induced nephropathy (cin) increases the likelihood of patient morbidity and mortality following coronary procedures. contrast agents cause an acute deterioration in renal function via the generation of reactive oxygen species. vitamin e (alpha tocopherol)was demonstrated to be anti-oxidant and anti-inflammation. the present study was designed to evaluate the administration of antioxidant vitamin e (alpha tocopherol) as a means of preventing cin in these patients.

Eligibility criteria:
inclusion criteria: * serum creatinine levels \> 1.2 mg/dl and baseline creatinine clearance levels \< 60 ml/min (as measured in their most recent sample,drawn within 2 months prior to the beginning of the study) exclusion criteria: * patients with acute kidney injury * end stage renal disease (requiring dialysis) * unstable renal function (as evidenced by a change in serum creatinine of \> 0.5 mg/dl, or \> 25%, within 14 days prior to the study) * allergy to any of the contrast agents * mechanical ventilation * suffered from congestive heart failure, cardiogenic shock or emergent angiography. * receiving nac, mannitol, diuretics, theophylline, dopamine, vitamin e or contrast agents within 14 days before the study

Keywords: alpha-tocopherol (vitamin e) contrast induced nephropathy chronic kidney disease coronary procedures
cognitive-behavioral intervention for worry, uncertainty, and insomnia for cancer survivors

Conditions: Anxiety Disorder; Worry; Uncertainty; Sleep Disorders; Insomnia; Fatigue; Pain; Depression; Cognitive-behavioral Therapy; Psychological Intervention; Esophageal Cancer; Pancreatic Cancer; Leukemia; Lung Cancer; Multiple Myeloma; Ovarian Neoplasm; Stage III or IV Cervical or Uterine Cancer; Stage IIIB, IIIC, or IV Breast Cancer; Glioblastoma Multiforme; Relapsed Lymphoma; Stage III or IV Colorectal Cancer; Stage IIIC or IV Melanoma

Summary: this randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors. counseling may reduce anxiety and insomnia as well as improve the well-being and quality of life of cancer survivors. this study also explores the neuro-immunologic correlates of anxiety and insomnia.

primary objectives: i. to complete a randomized pilot trial of a cognitive-behavioral anxiety-insomnia intervention to determine the impact of this intervention on patient worry, intolerance of uncertainty, and sleep efficiency. ii. explore the underlying endocrine and immune mechanisms responsible for a specific symptom cluster (anxiety-insomnia-depression-pain-fatigue) observed among advanced cancer patients. outline: patients are randomized to 1 of 2 treatment arms. arm i: patients wear a wrist actigraph, collect saliva samples, and complete a sleep diary and worry record daily in weeks 1 and 5. patients also receive education on the components of anxiety (physical cognitive, and behavioral) and practice relaxation techniques and behavioral sleep strategies in weeks 2-5. blood draw is optional. arm ii: patients wear a wrist actigraph, collect saliva samples, and complete a sleep diary and worry record daily in weeks 1 and 5. blood draw is also optional. this is a wait-list control arm, so patients in this arm, after a six-week period of treatment as usual with their oncologist, then receive the intervention.

Eligibility criteria:
inclusion criteria: * lung cancer * stage iii or iv colorectal cancer * pancreatic cancer * esophageal cancer * multiple myeloma * leukemia * stage iiic and iv melanoma * ovarian cancer * stage iii \& iv cervical cancer * stage iii \& iv uterine cancer * stage iiib, iiic, and iv breast cancer * glioblastoma multiforme * early relapse (\< 1 year) lymphoma exclusion criteria: * co-morbid immunologic disease (i.e. rheumatoid arthritis, systemic lupus) * neurologic disease (i.e. multiple sclerosis, parkinson's, alzheimer's) that would affect neuro-immune assessment or completion of study questionnaires * mania (if patient has bipolar disorder) * active substance abuse disorders such as alcohol dependence and cocaine abuse will also be excluded

Keywords: cancer cancer survivors worry insomnia symptoms fatigue depression anxiety
investigation for health efficacy of infrared-c radiation on diabetes patients in senior's activity center

Conditions: Diabetes Mellitus, Type 2

Summary: hyperglycemia caused by diabetes will bring us the long-term damage，it causes glycation. the combination of sugar molecules and protein molecules will transform to advanced glycation end products (ages) and produce a lot of free radicals to caused inflammatory reactions, forming various comorbidities, affecting the function of different organs, especially the eyes, kidneys, nervous system, heart, blood vessels and damage to bone structure and bone quality, which leads to bone loss. therefore, the development of alternative therapies is important for the treatment of diabetes. we assume the 4 months experiment can normalize subjects hba1c.

in the past research from our team, it was found that far infrared ray (fir) helps to reduce oxidative stress in the body and is expected to contribute to the treatment of diabetes. therefore, the team hopes to effectively reduce glycated hemoglobin (hba1c), fasting blood glucose (glu-ac), insulin (insulin), reduce the body's oxidative stress index, increase total antioxidant capacity (tac) inhibit the inflammatory response and reduce complications through 4 months of ir-c intervention. which expected to reduce the index of the nitrogen-type first collagen element (procollagen-i n -telopeptide, pinp) and c-telopeptide of type i collagen (ctx) bone loss index, enhance osteocalcin's index of bone growth indicators. along with the pittsburgh sleep quality index (psqi), numeric rating scale-knee (nrs-knee) and geriatric depression scale-15 (gds-15) to reduce the number of times the elderly take medication and improve their health and quality of life.

Eligibility criteria:
inclusion criteria: * hba1c higher than 6.8% or fasting blood sugar higher than 126mg/dl; * conscious, mental and cognitively normal; * no obstacles in action; * can read, write and communicate with mandarin, taiwanese and hakka. exclusion criteria: * inflammatory skin wounds on the neck, back, lower back or lower leg; * obstacles in communication; * people with disabilities, epilepsy, and other unacceptable warming treatments; * when the subject finds that he or she is unwell during the procedure, the experiment is terminated and take care by the medical staff.

Keywords: types 2 diabetes mellitus glycation ages hemoglobin a1c, hba1c fasting blood sugar, glu-ac insulin procollagen-i n-telopeptide, pinp c-telopeptide of type i collagen, ctx osteocalcin pittsburgh sleep quality index, psqi numeric rating scale-knee, nrs-knee geriatric depression scale-15, gds-15 total antioxidant capacity, tac infrared-c hyperglycemia
a study of zemplar® injection and hectorol® injection on intestinal absorption of calcium in chronic kidney disease

Conditions: Chronic Kidney Disease, Stage 5; Secondary Hyperparathyroidism

Summary: the purpose of this study is to evaluate the effects of zemplar® injection and hectorol® injection on intestinal calcium absorption in chronic kidney disease stage 5 subjects on hemodialysis.


Eligibility criteria:
inclusion criteria: * subject is \>= 20 years of age. * subject is diagnosed with ckd stage 5, and must be on maintenance (chronic) hemodialysis (hd) three times a week for at least 2 months prior to the screening visit and expected to remain on hd for the duration of the study. * if female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control: * condoms, sponge, foams, jellies, diaphragm or intrauterine device (iud) * contraceptives (oral or parenteral) for three months prior to study drug administration * in a monogamous relationship with a vasectomized partner * if female, subject is not breastfeeding and has a negative serum pregnancy test prior to the treatment phase. * subject has an intact pth value \> 200 pg/ml at screening only (or re-screening, if applicable). * subject has a serum calcium level \< 10.2 mg/dl at screening only (or re-screening, if applicable). * subject has a serum phosphorus level \< 6.5 mg/dl at screening only (or re-screening, if applicable). * subject has a caxp product \<= 65 at screening only (or re-screening, if applicable). * subject must voluntarily sign and date an informed consent, approved by an institutional review board (irb)/independent ethics committee (iec), prior to the conduct of any study-specific procedure. exclusion criteria: * subject has a history of an allergic reaction or significant sensitivity to vitamin d or vitamin d related compounds. * subject has chronic gastrointestinal disease, which in the investigator's opinion, may result in clinically significant gi malabsorption. * liver function defects defined as \> 2 times the upper limit of normal for liver enzyme (sgot/ast, sgpt/alt) levels. * subject has a hemoglobin level \< 9.0 g/dl. * subject is taking maintenance calcitonin, sensipar® (cinacalcet), glucocorticoids in an equivalent dose \> 5 mg prednisone daily, or other drugs that may affect calcium or bone metabolism within 2 weeks prior to screening, other than females on stable (same dose and product for 3 months) estrogen and/or progestin therapy. * for any reason, subject is considered by the investigator to be an unsuitable candidate to receive pharmacological doses of vitamin d. * subject has received any investigational drug within 4 weeks prior to the treatment phase.

Keywords: stage 5 chronic kidney disease (ckd)
patient education in children with functional gastrointestinal disorders

Conditions: Functional Gastrointestinal Disorders

Summary: this pilot-study aims to evaluate the effect size and feasibility of patient education for children and adolescents (age 8-17 years) with pain-predominant functional gastrointestinal disorders (irritable bowel syndrome, functional abdominal pain and functional dyspepsia according to the rome iii criteria).

the patient education will be provided in a group setting and the children will participate along with one of their parents. education consists of 2-hour long group sessions, given at 2 different occasions within a month. the hypothesis is that patient education will reduce gastrointestinal symptoms and pain and also improve quality of life in this group of patients.

Eligibility criteria:
inclusion criteria: * children and adolescents between 8-17 years (until their 18th birthday) who have been diagnosed with any of the diagnoses irritable bowel syndrome, functional dyspepsia or functional abdominal pain according to the rome iii criteria. * blood samples, with normal outcome, in terms of complete blood count (cbc), erythrocyte sedimentation rate (esr), anti-tissue transglutaminase antibody (ttg), and dipstick urinalysis. faecal calprotectin should be measured if diarrhea is present. exclusion criteria: * insufficient skills in the swedish language. * severe psychiatric comorbidity (as suicidality, psychosis etc). * severe somatic comorbidity.